The peripheral anionic site of acetylcholinesterase: Structure, functions and potential role in rational drug design

Current Pharmaceutical Design

Volumn 12, Issue 2, 2006, Pages 217-225

  Johnson, G ^a   Moore, S W ^a  

^a STELLENBOSCH UNIVERSITY   (South Africa)

Author keywords

Acetylcholinesterase; Allosterism; Inhibitors; Non cholinergic; Peripheral anionic site; Rational drug design

Indexed keywords

1,5 BIS(4 ALLYLDIMETHYLAMMONIUMPHENYL)PENTAN 3 ONE DIBROMIDE; ACETYLCHOLINESTERASE; AMYLOID BETA PROTEIN; ASPARTIC ACID; CARBAMIC ACID DERIVATIVE; CELL ADHESION MOLECULE; CHOLINESTERASE INHIBITOR; COLLAGEN TYPE 4; DECAMETHONIUM; DONEPEZIL; FASCICULIN; GALLAMINE; HUPERZINE A; LAMININ; ORGANOPHOSPHATE; ORGANOPHOSPHATE PESTICIDE; PROPIDIUM IODIDE; RETINOID; SERINE; SNAKE VENOM; TRYPTOPHAN; TYROSINE; ANION;

ACYLATION; ALLOSTERISM; ALZHEIMER DISEASE; AMYLOIDOSIS; ANTIBODY DETECTION; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; AUTOIMMUNE DISEASE; BINDING SITE; CANCER RESISTANCE; CANCER THERAPY; CATALYSIS; CELL ACTIVATION; COMPETITIVE INHIBITION; CONFORMATIONAL TRANSITION; CRYSTAL STRUCTURE; DEMENTIA; DOPAMINERGIC NERVE CELL; DRUG DESIGN; DRUG POTENCY; DRUG PROTEIN BINDING; DRUG STRUCTURE; DRUG TARGETING; ELECTRICITY; EMBRYO DEVELOPMENT; ENZYME ACTIVITY; ENZYME STRUCTURE; HUMAN; HYDROGEN BOND; IN VITRO STUDY; LYMPHOCYTE ACTIVATION; MYASTHENIA; NERVE REGENERATION; NERVOUS SYSTEM DEVELOPMENT; NEUROLOGIC DISEASE; NONHUMAN; PRIORITY JOURNAL; PROTEIN BINDING; PROTEIN PROTEIN INTERACTION; REVIEW; SEQUENCE HOMOLOGY; STRUCTURE ANALYSIS; SYNAPTOGENESIS; ANIMAL; CHEMISTRY; DRUG EFFECT; ELECTROCHEMISTRY; METABOLISM;

ACETYLCHOLINESTERASE; ANIMALS; ANIONS; BINDING SITES; CATALYSIS; CHOLINESTERASE INHIBITORS; DRUG DESIGN; ELECTROCHEMISTRY; HUMANS;

EID: 33644867844     PISSN: 13816128     EISSN: None     Source Type: Journal    
DOI: 10.2174/138161206775193127     Document Type: Review

References (106)

1. Holmquist M. Alpha/Beta hydrolase fold enzymes: structures, functions and mechanisms. Curr Protein Pept Sci 2000; 1: 209-235.
2. Hortsch M, Patel NH, Bieber AJ, Traquina ZR, Goodman CS. Drosophila neurotactin, a surface glycorprotein with homology to serine esterases is dynamically expressed dyring embryogenesis. Development 1990; 110: 1327-1340.
3. Olson PR, Fessler LI, Nelson RE, Sterne RE, Campbell AG, Fessler JH. Glutactin, a novel Drosophila basement membrane-related glycoprotein with sequence similarity to serine esterases. EMBO J 1990; 9: 1219-1227.
4. Auld VJ, Fetter RD, Broadie K, Goodman CS. Gliotactin, a novel transmembrane protein on peripheral glia, is required to form the blood-brain barrier in Drosophila. Cell 1995; 81: 757-767.
5. Ichtchenko K, Nguyen T, Sudhof TC. Structures, alternative splicing and neurexin binding of multiple neuroligins. J Biol Chem 1996: 271: 2676-2682.
6. Bomblies L, Biegelmann E, During V, Gerisch G, Kraft-Czepa H, Noegel AA, et al. Humbel BM.Membrane-enclosed crystals in Dictyostelium discoideum cells, consisting of developmentally regulated proteins with sequence similarities to known esterases. J Cell Biol 1990; 110: 669-679.
7. Schumacher M, Camp S, Maulet Y, Newton M, MacPhee-Quigley K, Taylor SS, et al. Primary structure of acetylcholinesterase; implications for regulation and function. Fed Proc 1986; 45: 2976-2981.
8. Raineri M, Modenisi P. Preliminary evidence for a cholinergic-like system in lichen morphogenesis. Histochem J 1986; 18: 647-657.
9. Delmonte Corrado MU, Politi H, Trielli F, Angelini C, Falugi C. Evidence for the presence of a mammalian-like cholinesterase in Paramecium primaurelia (Protista, Ciliophora) developmental cycle. J Exp Zool 1999; 283: 102-105.
10. Rubino S, Mann SK, Hori RT, Pinko C, Firtel RA. Molecular analysis of a developmentally regulated gene required for Dictyostelium aggregation. Dev Biol 1989; 131: 27-36.
11. Rosenberry TL. Acetylcholinesterase. Adv Enzymol Relat Areas Mol Biol 1975; 43: 103-218.
12. Sussman JL, Harel M, Frolow F, Oefner C, Goldman A, Toker L, et al. Atomic structure of acetylcholinesterase from Torpedo californica: a prototypic acetylcholine-binding protein. Science 1991; 253: 872-879.
13. Mallender WD, Szegletes T, Rosenberry TL. Acetylthiocholine binds to asp74 at the peripheral site of human acetylcholinesterase as the first step in the catalytic pathway. Biochemistry 2000; 39: 7753-7763.
14. Hosea NA, Radic Z, Tsigelny I, Berman HA, Quinn DM, Taylor P. Aspartate 74 as a primary determinant in acetylcholinesterase governing specificity to cationic organophosphonates. Biochemistry 1996; 35: 10995-11004.
15. Radic Z, Reiner E, Taylor P. Role of the peripheral anionic site on acetylcholinesterase: inhibition by substrates and coumarin derivatives. Mol Pharmacol 1991; 39: 98-104.
16. Johnson G, Moore SW. The adhesion function of acetylcholinesterase is located at the peripheral anionic site. Biochem Biophys Res Commun 1999; 258: 758-762.
17. Munoz FJ, Aldunate R, Inestrosa NC. Peripheral binding site is involved in the neurotrophic activity of acetylcholinesterase. Neuroreport 1999; 10: 3621-3625.
18. Inestrosa NC, Alvarez A, Perez CA, Moreno RD, Vicente M, Linker C, et al. Acetylcholinesterase acceleerates assembly of amyloid beta-peptides into Alzheimer's fibrils; possible role of the peripheral site of the enzyme. Neuron 1996; 16: 881-891.
19. Inestrosa NC, Alarcon R. Molecular interactions of acetylcholinesterase with senile plaques. J Physiol Paris 1998; 92: 341-344.
20. Bourne Y, Taylor P, Bougis PE, Marchot P. Crystal structure of mouse acetylcholinesterase. A peripheral site-occluding loop in a tetrameric assembly. J Biol Chem 1999; 274: 2963-2970.
21. Johnson G, Moore SW. Human acetylcholinesterase binds to mouse laminin-1 and human collagen IV by an electrostatic mechanism at the peripheral anionic site. Neurosci Lett 2003; 337: 37-40.
22. Li Y, Camp S, Taylor P. Tissue-specific expression and alternative mRNA processing of the mammalian acetylcholinesterase gene. J Biol Chem 1993; 268: 5790-5797.
23. Massoulie J. The origin of the molecular diversity and functional anchoring of cholinesterases. Neurosignals 2002; 11: 130-143.
24. Ordentlich A, Kronman C, Flashner Y, Leitner M, Segall Y, Ariel N, et al. Dissection of the human acetylcholinesterase active center determinants of substrate specificity. Identification of residues constituting the active site, the hydrophobic site and the acyl pocket. J Biol Chem 1993; 268: 17083-17095.
25. Radic Z, Pickering NA, Vellom DC, Camp S, Taylor P. Three distinct domains in the cholinesterase molecule confer selectivity for acetyl- and butyrylcholinesterase inhibitors. Biochemistry 1993; 32: 12074-12084.
26. Harel M, Schalk I, Ehrat-Sabatier L, Bouet F, Goeldner I, Sussman JL. Quaternary ligand binding to aromatic residues in the active site gorge of acetylcholinesterase. Proc Natl Acad Sci USA 1993; 90: 9031-9035.
27. Ordentlich A, Barak D, Kronman C, Ariel N, Segall Y, Velan B, et al. Functional characteristics of the oxyanion hole in human acetycholinesterase. J Biol Chem 1998; 273: 19509-19517.
28. Weise C, Kreienkamp HJ, Raba R, Pedak A, Aaviksaar A. Anionic subsites of the acetylcholinesterase from Torpedo californica: affinity labelling with the cationic reagent N, N-dimethyl-2-phenyl-aziridinium. EMBO J 1990; 9: 3885-8.
29. Shafferman A, Kronman C, Flashner Y, Leitner M, Ordentlich A, Gozes Y, et al. Mutagenesis of human acetylcholinesterase. Identification of residues involved in catalytic activity and in polypeptide folding. J Biol Chem 1992; 261: 17640-17648.
30. Cygler M, Schrag JD, Sussman JL, Harel M, Silman I, Gentry MK, et al. Relationship between sequence conservation and three-dimensional structure in a large family of esterases, lipases, and related proteins. Protein Sci 1993; 2: 366-382.
31. Velan B, Barak D, Ariel N, Leitner M, Bino T, Ordentlich A, et al. Structural modifications of the omega loop in human acetylcholinesterase. FEBS Lett 1996; 395: 22-28.
32. Faerman C, Ripoll D, Bon S, Le Feuvre Y, Morel N, Massoulie J, et al. Site-directed mutants designed to test back-door hypotheses of acetylcholinesterase function. FEBS Lett 1996; 386: 65-71.
33. Shi J, Tai K, McCammon JA, Taylor P, Johnson DA. Nanosecond dynamics of the mouse acetylcholinesterase cys69-cys96 omega loop. J Biol Chem 2003; 278: 30905-30911.
34. Bui JM, Tai Y, McCammon JA. Acetylcholinesterase: enhanced fluctuations and alternative routes to the active site in the complex with fasciculin-2. J Am Chem Soc 2004; 126: 7198-7205.
35. Botti SA, Felder CE, Silman I. Electrotactins: a class of adhesion proteins with conserved electrostatic and structural motifs. Protein Eng 1998; 11: 415-420.
36. Sanders M, Mathews B, Sutherland D, Soong W, Pezzementi L. Biochemical and molecular characterization of acetylcholinesterase from the hagfish Myxine glutinosa. Comp Biochem Physiol B Biochem Mol Biol 1996; 115: 97-109.
37. Barak D, Kronman C, Ordentlich A, Ariel N, Bromberg A, Marcus D, et al. Acetylcholinesterase peripheral anionic site degeneracy conferred by amino acid arrays sharing a common core. J Biol Chem 1994; 269: 6296-6305.
38. Kreienkamp HJ, Weise C, Raba R, Aaviksaar A, Hucho F. Anionic subsites of the catalytic center of acetylcholinesterase from Torpedo and from cobra venom. Proc Natl Acad Sci USA 1991; 88: 6117-6121.
39. Bourne Y, Kolb HC, Radic Z, Sharpless KB, Taylor P, Marchot P. Freeze-frame inhibitor captures acetylcholinesterase in a unique conformation. Proc Natl Acad Sci USA 2004; 101: 1449-1454.
40. Bourne Y, Taylor P, Marchot P. Acetylcholinesterase inhibition by fasciculin: crystal structure of the complex. Cell 1995; 83: 503-512.
41. Szegletes T, Mallender WD, Thomas PJ, Rosenberry TL. Substrate binding to the peripheral site of acetylcholinesterase initiates enzymatic catalysis. Substrate inhibition arises as a secondary effect. Biochemistry 1999; 38: 122-133.
42. Aldridge WN, Reiner E. Two types of inhibition by an organophosphorus compound: one the formation of phosphorylated enzyme and the other analogous to inhibition by substrate. Biochem J 1969; 115: 147-162.
43. Taylor P, Radic Z, Kreienkamp HJ, Maeda R, Luo Z, Fuentes ME, et al. Expression and ligand specificity of acetylcholinesterase and the nicotinic receptor: a tale of two cholinergic sites. Biochem Soc Trans 1994; 22: 740-745.
44. Kitz RJ, Braswell LM, Ginsburg S. On the question: is acetylcholinesterase an allosteric protein? Mol Pharmacol 1970; 6: 108-121.
45. Kitz RJ, Ginsburg S. The reaction of acetylcholinesterase (AChE) with some quaternary hydroxy aminophenols. Biochem Pharmacol 1968; 17: 525-532.
46. Kato G, Yung J, Ihnat M. Nuclear magnetic resonance studies on acetylcholinesterase. The use of atropine and eserine to probe binding sites. Mol Pharmacol 1970; 6: 588-596.
47. Changeux JP. Responses of acetylcholinesterase from Torpedo marmorata to salts curarizing agents. Mol Pharmacol 1966; 2: 369-392.
48. Barak D, Ordentlick A, Bromberg A, Kronman C, Marcus D, Lazar A, et al. Allosteric modulation of acetylcholinesterase activity by peripheral ligands involves a conformational transition of the anionic subsite. Biochemistry 1995; 34: 15444-15452.
49. Radic Z, Quinn DM, Vellom DC, Camp S, Taylor P. Allosteric control of acetylcholinesterase by fasciculin. J Biol Chem 1995; 270: 20391-20399.
50. Radic Z, Gibney G, Kawamoto S, MacPhee-Quigley K, Bongiorno C, Taylor P. Expression of recombinant acetylcholinesterase in a baculovirus system: kinetic properties of glutamate 199 mutants. Biochemistry 1992; 31: 9760-9767.
51. Grubic Z, Stalc A, Sentjuro M, Pecar S, Gentry MK, Doctor BP. Different effects of two peripheral anionic site-binding ligands on acetylcholinesterase active-site gorge topography revealed by electron paramagnetic resonance. Biochim Biophys Acta 1995; 1249: 155-160.
52. Shi J, Boyd AE, Radic Z, Taylor P. Reversibly bound and covalently attached ligands induce conformational changes in the omega loop, Cys69-Cys96, of mouse acetylcholinesterase. J Biol Chem 2001, 276: 42196-42204.
53. Shi J, Radic, Z, Taylor P. Inhibitors of different structure induce distinguishing conformations in the omega loop, Cys69-Cys96, of mouse acetylcholinesterase. J Biol Chem 2002, 277: 43301-43308.
54. 125I-fasciculin to rat brain acetylcholinesterase: the complex still binds diisopropyl fluorophosphate. J Biol Chem 1993; 268: 12458-12467.
55. Vellom DC, Radic Z, Li Y, Pickering NA, Camp S, Taylor P. Amino acid residues controlling acetylcholinesterase and butyrylcholinesterase specificity. Biochemistry 1993; 32: 12-17.
56. Kryger G, Silman I, Sussman JL. Three-dimensional structure of a complex of E2020 with acetylcholinesterase from Torpedo californica. J Physiol Paris 1998; 92: 191-194.
57. Felder CE, Harel M, Silman I, Sussman JL. Structure of a complex of the potent and specific inhibitor BW284C51 with Torpedo californica acetylcholinesterase. Acta Crystallogr D Biol Crystallogr 2002; 58: 1765-1771.
58. Dvir H, Jiang HL, Wong DM, Harel M, Chetrit M, He XC, et al. X-ray structure of Torpedo californica acetylcholinesterase complexed with (-)-huperzine A (-)-huperzine B: Structural evidence for an active site rearrangement. Biochemistry 2002; 41: 10810-10818.
59. Szegletes T, Mallender WD, Rosenberry TL. Nonequilibrium analysis alters the mechamistic interpretation of inhibition of acetylcholinesterase by peripheral site ligands. Biochemistry 1998, 37: 4206-4216.
60. De Ferrari GV, Mallender WD, Inestrosa NC, Rosenberry TL. Thioflavin T is a fluorescent probe of the acetylcholinesterase peripheral site that reveals conformational interactions between the peripheral and acylation sites. J Biol Chem 2001; 276: 23282-23287.
61. Radic Z, Duran R, Vellom DC, Li Y, Cervenansky C, Taylor P. Site of fasciculin interaction with acetylcholinesterase. J Biol Chem 1994; 269: 11233-11239.
62. Harel M, Kleywegt GJ, Ravelli RB, Silman I, Sussman JL. Crystal structure of an acetylcholinesterase-fasciculin complex: interaction of a three-fingered toxin from snake venom with its target. Structure 1995; 3: 1355-1366.
63. Shafferman A, Ordentlich A, Barak D, Kronman C, Ber R, Bino T, et al. Electrostatic attraction by surface charge does not contribute to the catalytic efficiency of acetylcholinesterase. EMBO J 1994; 13: 3448-3455.
64. Felder CE, Botti SA, Lifson S, Silman I, Sussman JL. External and internal electrostatic potentials of cholinesterase models. J Mol Graph Model 1997; 15: 318-327.
65. Tan RC, Truong TN, McCammon JA, Sussman JL. Acetylcholinesterase: electrostatic steering increases the rate of ligand binding. Biochemistry 1993; 32: 401-403.
66. Masson P, Froment MT, Bartels CF, Lockridge O. Asp7O in the peripheral anionic site of human butyrlcholinesterase. Eur J Biochem 1996; 235: 36-48.
67. Crone HD. The influence of ionic strength on the interaction of quaternary drugs with mammalian acetylcholinesterase in relation to possible regulatory effects. J Neurochem 1973; 20: 225-236.
68. Radic Z, Kirchhoff PD, Quinn DM, McCammon JA, Taylor P. Electrostatic influence on the kinetics of ligand binding to acetylcholinesterase. Distinctions between active center ligands and fasciculin. J Biol Chem 1997; 272: 23265-23267.
69. Layer PG, Willbold E. Novel functions of cholinesterases in development, physiology and disease. Prog Histochem Cytochem 1995; 29: 1-94.
70. Greenfield S, Vaux DJ. Parkinson's disease, Alzheimer's disease and motor neurone disease: identifying a common mechanism. Neuroscience 2002; 113: 485-492.
71. Layer PG, Weikert T, Alber R. Cholinesterases regulate neurite growth of chick nerve cells in vitro by means of a non-enzymatic mechanism. Cell Tissue Res 1993; 272: 219-226.
72. Small DH, Reed G, Whitefield B, Nurcombe V. Cholinergic regulation of neurite outgrowth from isolated chick sympathetic neurons in culture. J Neurosci 1995; 15: 144-151.
73. Bigbee JW, Sharma KV, Chan EL, Bogler O. Evidence for the direct role of acetylcholinesteras in neurite outgrowth in primary dorsal root ganglion neurons. Brain Res 2000; 861: 354-362.
74. Karpel R, Sternfeld M, Ginzberg D, Guhl E, Graessmann A, Soreq H. Overexpression of laternative human acetylcholinesterase forms modulates process extensions in cultured glioma cells. J Neurochem 1996; 66: 114-123.
75. Koenigsberger C, Chiappa S, Brimijoin S. Neurite differentiation is modulated in neuroblastoma cells engineered for altered acetylcholinesterase expression. J Neurochem 1997: 69: 1389-1397.
76. Johnson G, Moore SW. Cholinesterases modulate cell adhesion in human neuroblastoma cells in vitro. Int J Dev Neurosci 2000; 18: 781-790.
77. Sternfeld M, Ming G, Song H, Sela K, Timberg R, Poo M, et al. Acetylcholinesterase enhances neurite growth and synapse development through alternative contributions of its hydrolytic capacity, core protein and variable C termini. J Neurosci 1998; 18: 1240-1249.
78. Holmes C, Jones SA, Budd TC, Greenfield SA. Non-cholinergic trophic action of recombinant acetylcholinesterase on mid-brain dopaminergic neurons. J Neurosci Res 2000; 49: 207-218.
79. Yang L, He HY, Zhang XJ. Increased expression of intranuclear acetylcholinesterase involved in apoptosis of SK-N-SH cells. Neurosci Res 2002; 42: 261-268.
80. Zhang XJ, Yang L, Zhao Q, Caen JP, He HY, Jin QH, et al. Induction of acetylcholinesterase expression during apoptosis in various cell types. Cell Death Differ 2002; 9: 790-800.
81. Srivatsan M, Peretz B. Acetylcholinesterase promotes regeneration of neurites in cultured adult neurons of Aplysia. Neuroscience 1997; 77: 9211-9231.
82. Soreq H, Patinkin D, Lev-Lehman E, Grifman M, Girzberg D, Eckstein F, et al. Antisense oligonucleotide inhibition of acetylcholinesterase gene expression induces progenitor cell expansion and suppresses hematopoietic apoptosis ex vivo. Proc Natl Acad Sci USA 1994; 91: 7907-7911.
83. Kawashima K, Fujii T. Extraneuronal cholinergic system in lymphocytes. Pharmacol Ther 2000; 86: 29-48.
84. Johnson G, Moore SW. Identification of a structural site on acetylcholinesterase that promotes neurite outgrowth and binds laminin-1 and collagen IV. Biochem Biophys Res Commun 2004; 319: 448-455.
85. De Ferrari GV, Canales MA, Shin I, Weiner LM, Silman I, Inestrosa NC. A structural motif of acetylcholinesterase that promotes amyloid beta-peptide fibril formation. Biochemistry 2001; 40: 10447-10457.
86. Xie W, Stribley JA, Chatonnet A, Wilder PJ, Rizzino A, McComb RD, et al. Postnatal developmental delay and supersensitivity to organophosphate in gene-targeted mice lacking acetylcholinesterase. J Pharmacol Exp Ther 2000; 29: 896-902.
87. Johnson G, Moore SW. Catalytic antibodies with acetylcholinesterase activity. J Immumol Methods 2002; 269: 13-28.
88. Grifman M, Galyam N Seidman S, Soreq H. Functional redundancy of acetylcholinesterase and neuroligin in mammalian neuritogenesis. Proc Natl Acad Sci USA 1999; 95: 13935-13940.
89. Bourne Y, Taylor P, Radic, Z, Marchot P. Structural insights into ligand interactions at the acetylcholinesterase peripheral anionic site. EMBO J 2003; 22: 1-12.
90. Boyd AE, Dunlop CS, Wong L, Radic Z, Taylor P, Johnson DA. Nanosecond dynamics of acetylcholinesterase near the active center gorge. J Biol Chem 2004; 279: 26612-26618.
91. Fetrow JS. Omega loops: nonregular secondary structures signficant in protein function and stability. FASEB J 1995; 9: 708-717.
92. Savini L, Gaeta A, Fatturusso C, Catalanotti B, Campiani G, Chiasserini L, et al. Specific targeting of acetylcholinesterase and butyrylcholinesterase recognition sites. Rational design of novel, selective and highly potent cholinesterase inhibitors. J Med Chem 2003; 46: 1-4.
93. 2+ channels and nicotinic receptors. Bioorg Med Chem 2004; 12: 2199-2218.
94. Hebert LE, Scherr PA, Becklett LA, Albert MS, Pilgrim DM, Chown MJ, et al. Age-specific incidence of Alzheimer's disease in a community population. JAMA 1995; 273: 1354-1359.
95. Barril X, Kalko SG, Orozco M, Luque FJ. Rational design of reversible acetylcholinesterase inhibitors. Mini Rev Med Chem 2002; 2: 27-36.
96. Castro A, Martinez A. Peripheral and dual binding site acetylcholinesterase inhibitors: implications in treatment of Alzheimer's disease. Mini Rev Med Chem 2001; 1: 267-272.
97. Giacobini E. Cholinesterases: new roles in brain function and in Alzheimer's disease. Neurochem Res 2003; 28: 515-522.
98. Pang YP, Kollmeyer TM, Hong F, Lee JC, Hammond PI, Haugabouk SP, et al. Rational design of alkylene-linked bis-pyridiniumal-doximes as improved acetylcholinesterase reactivators. Chem Biol 2002; 10: 491-502.
99. Nam NH, Parang K. Current targets for anticancer drug discovery. Curr Drug Targets 2003; 4: 159-179.
100. Freemantle SJ, Spinella MJ, Dmitrovsky R. Retinoids in cancer therapy and chemoprevention: promise meets resistance. Oncogene 2003; 22: 7305-7315.
101. Ortiz MA, Bayar Y, Lopez-Hernandez FJ, Piedrafita FJ. Retinoids in combination therapies for the treatment of cancer: mechanisms and perspectives. Drug Resist Updat 2002; 5: 162-175.
102. Tang J, Yuan J, Hao H. Anti-acetylcholinesterase antibody in myasthenic syndrome. Chin Med J (Engl) 1997; 110: 698-700.
103. Lidar T, Christian A, Yakar S, Langevitz P, Zeilig G, Ohry A, et al. Clinically insignificant (natural) autoantibodies against acetyl cholinesterase in the sera of patients with a variety of neurologic, muscular and autoimmune diseases. Immunol Left 1997; 55: 79-84.
104. Mappouras DG, Philippou G, Haralambous S. Antibodies to acetylcholinesterase cross-reacting with thyroglobulin in myasthenia gravis and Graves's disease. Clin Exp Immunol 1995; 100: 336-343.
105. Bartels CF, Zelinski T, Lockridge O. Mutation at codon 322 in the human acetylcholinesterase (ACHE) gene accounts for YT blood group polyrmorphism. Am J Hum Genet 1993; 52: 928-936.
106. Izadyar L, Friboulet A, Remy M-H, Roseto A, Thomas D. Monoclonal anti-idiotypic antibodies as functional internal images of enzyme active sites: production of a catalytic antibody with a cholinesterase activity. Proc Natl Acad Sci USA 1993; 90: 8876-8880.